GW Pharmaceuticals

GW Pharmaceuticals

Verified
Cannabinoid prescription medicines developer

Launch date
Employees
Ownership
Market cap
-
Net debt
-
Firm valuation
$7.2b (Public information from Feb 2021)
Histon England (HQ)

Financials

Edit
Revenues, earnings & profits over time
USD2016201720182019202020212022E
Revenues-10.6m19.8m411m696m711m939m
% growth--88 %1973 %69 %2 %32 %
EBITDA(110m)(210m)(388m)(144m)(51.5m)86m197m
% EBITDA margin-(1988 %)(1960 %)(35 %)(7 %)12 %21 %
Profit110m(224m)(403m)(11.9m)(76.6m)19m160m
% profit margin-(2125 %)(2033 %)(3 %)(11 %)3 %17 %
EV / revenue-418.4x158.9x8.7x5.9x11.9x-
EV / EBITDA--21.1x-8.1x-24.8x-79.8x98.3x-
R&D budget123m138m147m140m---
R&D % of revenue-1302 %744 %34 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
N/A$31m
Valuation: $120m
IPO
N/A$87.9mPost IPO Equity
N/A$179mPost IPO Equity
*
N/A$290mPost IPO Equity
*
N/A$317mPost IPO Equity
*
N/A€300mPost IPO Equity
$7.2b
Valuation: $7.2b
Acquisition
Total Funding-

Recent News about GW Pharmaceuticals

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.